. Reported event rates and time-to-event data were pooled and entered into a microsimulation model to calculate life expectancy and lifetime event risk. Ninety-nine publications were included (13 129 patients; total follow-up: 93 408 patient-years, pooled mean follow-up: 7.9±5.3 years). Pooled mean age at surgery was 9.4±5.5 years for children and 41.9±11.4 for adults. For children and adults, respectively, pooled early mortality risk was 4.19% (95% CI, 3.21-5.46) and 2.01% (95% CI, 1.44-2.82), late mortality rate was 0.54%/y (95% CI, 0.42-0.70) and 0.59%/y (95% CI, 0.46-0.76), autograft reintervention 1.28%/y (95% CI, 0.99-1.66) and 0.83%/y (95% CI, 0.68-1.01), and right ventricular outflow tract reintervention 1.97%/y (95% CI, 1.64-2.36) and 0.47%/y (95% CI, 0.37-0.59). Pooled thromboembolism and bleeding rates were low and comparable to the general population. Lifetime risks of autograft and right ventricular outflow tract reintervention were, respectively, 94% and 100% for children and 49% and 19% for a 45-year-old. Estimated life expectancy after surgery was 59 years for children (general population: 64 years) and 30 years for a 45 years old (general population: 31 years).
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eplacement of the aortic valve with a pulmonary autograft (the Ross procedure) was introduced in the late 1960s by Donald Ross.
1 It provides many benefits over other options for aortic valve replacement (AVR) in children and young adults because of the favorable hemodynamic characteristics, low risk of endocarditis, low thrombogenicity, avoidance of anticoagulation therapy, and the diameter increase it shows along with somatic growth. 2 However, the Ross procedure is a technically demanding operation, and both the autograft in aortic position and the valve substitute in the right ventricular outflow tract (RVOT) are susceptible to valve deterioration and subsequent reintervention over time.
Reports on outcome after the Ross procedure are scattered, and although survival after this procedure is reported almost uniformly as excellent, rates of valverelated morbidity, especially autograft and allograft deterioration and reintervention, vary strongly among reports. This makes it difficult to draw inferences on what patients can be expected to face after the Ross procedure, information essential in guiding decisionmaking in children and young adults requiring AVR.
Since the publication of a prior systematic review on reported outcome after the Ross procedure by our group in 2009, 2 a wealth of additional patient series has been published, substantially longer follow-up has been accrued of the included patients, and our group has implemented advanced methods of meta-analysis of time-to-event data and microsimulation that allow for a much better insight into long-term outcome in these patients. We therefore provide an update of the systematic literature search, applying the latest methods of meta-analysis and calculating microsimulationbased estimates of age-specific life expectancy and lifetime risk of valve-related events.
METHODS

Search Strategy and Selection of Studies
This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines 3 and registered in the PROSPERO registry (CRD42016039676). The data, analytic methods, and study materials will be made available on request to the corresponding author.
On November 22, 2017, Embase, MEDLINE, Web of Science, The Cochrane Library, and Google Scholar were searched by a biomedical information specialist using keywords related to the Ross procedure/pulmonary autograft (Supplement I in the Data Supplement).
All studies were screened by 2 independent reviewers (J.R.G. Etnel, S.A. Huygens). Observational studies and randomized controlled trials reporting clinical outcome after the Ross procedure published in English after January 1, 2000, were considered for inclusion. Studies limited to patients with preexisting comorbidities or a history of previous AVR were excluded. Studies with a study size <20 patients or focusing only on certain aortic/ pulmonary valve/annulus/root sizes were also excluded. In case of multiple publications on overlapping study populations, the publication with the greatest total follow-up in patient-years or overall completeness of data was included for each outcome of interest separately. In case of disagreement between the reviewers, a consensus was negotiated.
Data Extraction
Microsoft Office Excel 2010 (Microsoft Corp, Redmond, WA) was used for data extraction. Data were extracted independently by 2 reviewers (J.R.G. Etnel, P. Grashuis) After data extraction, each reviewer verified the other reviewer's data entries. Recorded study characteristics, baseline patient characteristics, operative characteristics and outcome events are listed in Supplement I in the Data Supplement. Functional class was defined according to the New York Heart Association for adults and Ross 4 for children. Morbidity and mortality were documented according to the 2008 guidelines by Akins et al. 5 Early outcome events were defined as occurring within the first 30 postoperative days, regardless of the patient's location, and late outcome events were defined as occurring after the first 30 postoperative days. If total follow-up duration in patientyears was not reported, it was calculated by multiplying the number of patients with the mean follow-up duration of that study.
WHAT IS KNOWN
• Reports on outcome after the Ross procedure are scattered, and although survival after this procedure is reported almost uniformly as excellent, rates of valve-related morbidity, especially autograft and allograft deterioration and reintervention, vary strongly among reports.
• This makes it difficult to draw inferences on what patients can be expected to face after the Ross procedure, information essential in guiding decision-making in children and young adults requiring aortic valve replacement.
WHAT THIS STUDY ADDS
• Our advanced methods of meta-analysis of timeto-event data and microsimulation in conjunction with the large sample size provide robust long-term outcome estimates that allow for a unique insight into what patients can be expected to face during the course of their lives after undergoing the Ross procedure, which represents valuable information to patients and clinicians in a meaningful format.
• This provides the opportunity to provide patients and clinicians the essential information they need for effective decision-making.
• Our methodology also provides opportunities for patient-tailored decision-making by allowing for the possibility to generate patient-tailored outcome estimates.
Statistical Analyses
Statistical software used is listed in Supplement I in the Data Supplement. Continuous variables are presented as mean±SD. Categorical variables are presented as counts and percentages. Linearized event occurrence rates (constant hazard rates over time) are presented as percentages per year.
For all analyses, studies were grouped by age: pediatric (reported as concerning only children and mean age <18 years), adult (reported as concerning only adults and mean age ≥18 years), and all ages (combined pediatric and adult series). Pooled baseline patient characteristics were calculated with the use of sample size weighting. Early risks of mortality and linearized occurrence rates of late morbidity and mortality were calculated for each individual study and pooled with the use of inverse variance weighting in a random-effects model according to the DerSimonian and Laird method. Outcomes were pooled on a logarithmic scale, as the Shapiro-Wilk test revealed a significantly skewed distribution among the included studies in the majority of outcome measures. Inverse variance weighting was conducted according to the number of patients for early mortality and according to the number of patient-years of follow-up for late events. In case a particular event was reported not to occur in an individual study, it was assumed that 0.5 patient experienced that event for the purpose of inverse variance weighting (continuity correction). Cochran's Q statistic and the I 2 statistic were used to assess heterogeneity between studies. Potential causes of heterogeneity were explored by investigating the effect of all baseline patient characteristics and operative details listed in Table 1 as well as study design (retrospective versus prospective/randomized controlled trial) and median year of surgery by means of univariable random-effects meta-regression. The influence of potential publication bias on pooled outcome was investigated by conducting sensitivity analyses by temporarily excluding the smallest quartile (by sample size) of included studies in the all ages group.
Kaplan-Meier Meta-Analysis
Pooled Kaplan-Meier time-to-event meta-analysis was conducted by extrapolating and pooling estimates of individual patient time-to-event data from published Kaplan-Meier curves for survival and reintervention. Published Kaplan-Meier curves were digitized, and an estimate of the individual patient time-to-event data was then extrapolated from the digitized curve coordinates, assuming a constant rate of censorship between each time point at which the number of patients at risk was specified. 6 If there were no Kaplan-Meier curves available, but time points of each event were reported or there were no events, the individual patient time-to-event data were manually reconstructed up to a maximum follow-up of the mean follow-up +2 SDs, under the same assumption of a constant rate of censorship. Reconstructed individual patient time-to-event data of each study were then combined.
Microsimulation
A microsimulation model based on the pooled outcome estimates of our meta-analysis was used to calculate age-specific life expectancy and lifetime risk of valve-related morbidity. 7, 8 A description of the concept of the microsimulation model and a schematic overview of the hypothetical scenario that each simulated patient is run through are provided in Supplement I in the Data Supplement.
The operative mortality risk, the occurrence rate of each valve-related event, and the risk of mortality and reintervention as a direct result of each of these valve-related events were obtained from our meta-analysis. Separate estimates were obtained for children and adults from the respective subgroup analyses of our meta-analysis. The hazard of structural valve deterioration of the autograft and RVOT conduit were assumed to be time-varying and were modeled by fitting a Gompertz distribution to our pooled time-to-event data. The hazards of all other events were assumed to be constant over time. Additional excess mortality not directly resulting from valve-related events was estimated for the all ages, pediatric and adult subgroups separately using the least squares method (details in Supplement I in the Data Supplement). The background mortality of the general population was obtained for the pooled median year of surgery among included studies (2001, assuming a constant incidence rate over time in each study) and for the regions that the majority of the included study population originated from (Europe, 52% of patients; North America, 34% of patients) from the World Health Organization Global Health Observatory Data Repository for Europe and from the US Life Tables for North America. 9, 10 To obtain estimates of life expectancy and lifetime risk of valve-related morbidity, taking into account both first-order uncertainty (random variability in outcomes between identical patients) and second-order uncertainty (uncertainty in the input parameter estimates), probabilistic sensitivity analysis was conducted. The microsimulation model was run iteratively for 500 simulations with a sample size of 1000 patients per simulation (these amounts were based on the methods described by O'Hagan et al 11 ). In each of the 500 simulations, the values of the input parameters were randomly drawn from distributions corresponding with each parameter's point estimate and variance, obtained from the meta-analysis as described above. This yielded a complete set of outcome estimates for each of the 500 simulated patient populations. For each outcome measure, the mean of outcome estimates across all 500 simulated populations was considered the point estimate of outcome, and the 2.5th and 97.5th percentile were considered the lower and upper limits of the 95% credible interval, respectively.
To obtain age-specific estimates, this process was repeated separately for the pediatric group at the pooled mean age and SD of that subgroup (9.4±5.5 years) and also for the adults for the specific ages 25, 35, 45, and 55 years and at the male/female ratio obtained from our meta-analysis (pediatric 70.6% male, adult 73.0% male).
For the purposes of internal validation, the model was additionally run for 10 000 iterations at the pooled mean age (30.9±11.5 years) and pooled male/female ratio (72.6% male) of the all ages group, excluding early mortality. The actuarial survival curve obtained from this model was then plotted against the pooled overall survival curve observed in our Kaplan-Meier meta-analysis, excluding early mortality.
RESULTS
The systematic literature search identified 4252 publications, of which 99 were included in the meta-analysis, encompassing a total of 13 129 patients with 93 408 patient-years of follow-up (pooled mean follow-up: 7.9±5.3 years) ( Figure 1 ). Supplement II in the Data Supplement represents the characteristics of the included studies (references listed in Supplement VII in the Data Supplement).
Pooled baseline patient characteristics are shown in Table 1 .
Pooled risks of early mortality and pooled linearized occurrence rates of late mortality and late morbid events are presented in Table 2 (individual study estimates are presented in Supplement III in the Data Supplement). Early morbidity was reported too inconsistently to be included in the analyses. Pooled Kaplan-Meier curves of freedom from all-cause mortality, autograft reintervention, and RVOT reintervention are shown in Figures 2 through 4, respectively.
Microsimulation-based age-specific estimates of lifetime risk of valve-related morbidity and life expectancy are shown in Figures 5 and 6 , respectively. The microsimulation model calibrated well with the pooled mortality observed in our meta-analysis (Supplement IV in the Data Supplement). Least squares regression of survival estimates from the microsimulation model (excluding early mortality) versus those obtained from the metaanalysis of time-to-event data (excluding early mortality) revealed that excess mortality, not directly related to valve-related events, was zero in the pediatric, adult, and all ages groups alike (Supplement V in the Data Supplement). For children, life expectancy after surgery (58.9 years; 95% credible interval [CI], 56.9-60.9) was 92.1% of that in the age-and sex-matched general population (64.0 years), for a 25- The sum of the number of studies in the subgroups of included studies is greater than the total of 99 included studies, because of inclusion in multiple subgroups when possible. 1 Including 3 studies with both pediatric and adult subgroups.
Heterogeneity
There was substantial heterogeneity in early mortality, late mortality, reintervention, endocarditis, and bleeding.
Univariable random-effects meta-regression (Supplement VI in the Data Supplement) in the all ages group showed that studies with higher early mortality reported shorter mean follow-up (P<0.001), lower mean Data presented as mean±SD or percentage (range). AV indicates aortic valve; AVR, aortic valve replacement; CABG, coronary artery bypass grafting; NYHA, New York Heart Association; Preop., preoperative; and RVOT, right ventricular outflow tract.
*Twenty-seven pediatric+31 adult+33 unique studies.
age at surgery (P=0.003), higher preoperative NYHA/ Ross class (P=0.031), more preoperative endocarditis (P=0.003), less frequent use of allografts for RVOT reconstruction (P=0.005), more concomitant valve procedures, (P=0.031), and less concomitant ascending aortic surgery (P<0.001).
Higher late mortality was associated with shorter mean follow-up (P=0.012), higher mean age at surgery (P=0.039), more urgent operations (P<0.001), and more preoperative endocarditis (P<0.001).
Higher reintervention rates were associated with lower mean age at surgery (P<0.001), more preoperative combined aortic stenosis and regurgitation (P=0.011), more previous cardiac interventions (P=0.014), in particular previous aortic valve interventions (P<0.001), and more frequent concomitant annular enlargement procedures (P<0.001).
Higher postoperative endocarditis rates were associated with shorter mean follow-up (P<0.001), less bicuspid aortic valve (P=0.004), and more frequent use of total root replacement (P=0.007) and more frequent use of bioprostheses for RVOT reconstruction (P=002).
Higher postoperative bleeding rates were associated with shorter mean follow-up (P=0.001), higher proportions of preoperative endocarditis (P<0.001), and more concomitant valve procedures (P<0.001).
DISCUSSION
This study shows that the Ross procedure, when applied in a broad population of children and young adults, is associated with low early and late mortality, with a life expectancy after surgery of ≈90% to 95% of the life expectancy in the age-and sex-matched general population, depending on patient age at surgery. Thromboembolism, bleeding, and endocarditis rates are low. However, it also underlines the most important drawback of the Ross procedure: substantial late structural valve deterioration of both the autograft and the RVOT conduit, and subsequently high age-dependent reintervention rates, with lifetime risk of autograft reintervention ranging from 94% for children to 32% for 55-year-olds and for the RVOT conduit ranging from 100% for children to 14% for 55-year-olds. RVOT conduit deterioration and subsequent reintervention rates are significantly higher among children undergoing the Ross procedure compared with adults and represent the predominant indication for reintervention in these children.
Mortality
Our results show that the Ross procedure is associated with low early mortality and excellent late survival with 15-year actuarial survival of 93.5% for children and 91.9% for adults and life expectancy 90% to 95% of the age-and sex-matched general population. Excess mortality not directly related to valve-related events is very low if not zero in these patients.
This mortality is substantially lower than the mortality reported after mechanical AVR, in children and adults alike, despite the considerably higher reintervention rates after the Ross procedure. 12, 13 The favorable hemodynamics of the autograft in comparison with mechanical prostheses may play a role in this observed difference in mortality.
14 Furthermore, the higher mortality after mechanical AVR may be attributable in part to the thrombogenicity of mechanical valve prostheses and the subsequent requirement for anticoagulation treatment and the associated bleeding risks. 15 The often unstable International Normalized Ratio (INR) management may play a major role in this anticoagulation-related excess mortality risk after mechanical AVR, as a propensity-matched study by Mokhles et al 16 has previously demonstrated that, with optimal self-management anticoagulation, mechanical AVR offers excellent late survival comparable to the Ross procedure. However, this study by Mokhles et al 16 also illustrates the challenges that possible differences in patient selection pose in comparisons between the Ross procedure and mechanical AVR. Thus, when comparing survival differences between the Ross procedure and other valve substitutes, possible differences in patient characteristics and concomitant procedures performed at the time of surgery should be taken into account. Compared with published data on children and adults undergoing mechanical AVR, patients undergoing the Ross procedure are on average slightly younger, less frequently have rheumatic or degenerative disease and more frequently have congenital disease, but also have more frequently undergone prior cardiac interventions and undergo concomitant procedures slightly more often. 12, 13 Furthermore, the difference in life expectancy between patients after the Ross procedure and the general population appears to be slightly greater in children than in adults, although it should be taken into consideration that a large proportion of the mortality in the pediatric population may be attributable to neonates and infants rather than older children, as has been previously demonstrated.
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Autograft Deterioration
Both the autograft and RVOT conduit are subject to structural valve deterioration over time.
Subsequently, almost all patients that undergo the Ross procedure at age 25 or younger are projected to undergo autograft reintervention at some point during their lifetime, predominantly because of structural valve deterioration. For older adults, this lifetime risk lies between 32% and 68%, decreasing with increasing age at surgery.
After autograft root replacement, the main mechanism of autograft deterioration is progressive autograft regurgitation because of dilatation of the neoaortic root and may be explained by factors such as age, preoperative aortic regurgitation, preoperative aortic annulus dilatation, and underlying cause of disease. [17] [18] [19] [20] Considering the strong influence of these patientrelated factors on outcome, careful patient selection and patient-tailored decision-making are essential in achieving optimal outcome after the Ross procedure.
Given the technical complexity of the procedure, variation in surgical technique and surgeon and center volume may also affect long-term autograft function. For instance, subcoronary implantation, the inclusion technique, external prosthetic or pericardial support, and annuloplasty have all been proposed to provide a mechanically more durable result than full unsupported root replacement, with less neoaortic dilatation and subsequent regurgitation. [21] [22] [23] However, these techniques are only applied in a few centers. The technically demanding nature of these techniques and subsequent risk of distortion of the neoaortic valve apparatus remains a concern, particularly among surgeons less familiar with these techniques. 24 Furthermore, the acute increase in mechanical stress on the autograft associated with transplanting the pulmonary valve apparatus from the pulmonary to the systemic circulation is also thought to play a role in autograft dilatation and deterioration. 25 In this light, strict postoperative systemic blood pressure control, especially in the first few months postoperative before any remodeling has occurred, has been proposed as a means to further reduce allograft dilation. The effectiveness thereof remains to be elucidated. Error bars represent 95% credible intervals. If no error bars are displayed, the entire credible interval lies above 100%, because of a high probability of that particular event occurring multiple times sequentially in the same patient. The hazard of structural valve deterioration of the autograft and right ventricular outflow tract (RVOT) conduit were assumed to be time-varying and were modeled by fitting a Gompertz distribution to our pooled time-to-event data. The hazards of all other events were assumed to be constant over time. NSVD indicates nonstructural valve dysfunction; and SVD, structural valve deterioration. Error bars represent 95% credible intervals. The hazard of structural valve deterioration of the autograft and right ventricular outflow tract (RVOT) conduit were assumed to be time-varying and were modeled by fitting a Gompertz distribution to our pooled time-to-event data. The hazards of all other events were assumed to be constant over time.
Although reintervention remains a concern, continued improvements in surgical techniques and perioperative management have led to vast improvements in the safety of reoperative aortic valve surgery over the years. Subsequently, reoperations can currently be successfully performed with low mortality. 23 Unfortunately, when patients undergo autograft reintervention, the advantages of the Ross procedure are often lost because the autograft is often replaced with a mechanical valve. 23 However, in cases of autograft dysfunction because of root dilatation with intact autograft valve leaflets or in cases in which the valve leaflets can be successfully repaired, the increasing experience with valve-sparing autograft reinterventions provides increasing opportunities for long-term preservation of the benefits of the Ross procedure.
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RVOT Conduit Deterioration
Although usually less life-threatening, deterioration of the RVOT conduit does pose a substantial additional reintervention hazard, especially in children.
Structural RVOT conduit deterioration is a complex multifactorial process that is not yet well defined. Contrary to the predominant regurgitation seen in autografts, deterioration of the RVOT conduit, most commonly an allograft, is characterized mostly by progressive stenosis. 27 In allografts, immunologic factors are thought to play a role in RVOT conduit degeneration, as host immune response and AB0 blood group and human leukocyte antigen patient-donor mismatch have been demonstrated to be associated with increased structural RVOT allograft failure. 28, 29 In response, decellularization techniques have been developed that aim to reduce immune response and promote autologous cell repopulation by removing donor cells from the allograft while maintaining an intact extracellular matrix. There is some early clinical experience with the application of such allografts in the Ross procedure that demonstrates satisfactory hemodynamic function. [40] [41] [42] [43] [44] However, longer follow-up and accumulation of larger patient series is required to produce more definitive evidence on the hypothesized effect of decellularization.
Age is another important factor related to RVOT conduit degeneration, with younger age being associated with higher rates of valve degeneration. This is also clearly reflected by our results, with significantly higher RVOT reintervention rates in the pediatric subgroup compared with the adult subgroup. Even higher rates of RVOT reintervention have been previously reported in neonates and infants (4.30%/y) compared with our pediatric subgroup which also includes older children. 12 Although the exact mechanism that underlies the effect of age on RVOT conduit degeneration is not entirely understood, age-related differences in calcium metabolism, immune activity, somatic growth, and hemodynamics are hypothesized to play a role. [45] [46] [47] [48] Although the additional reintervention risk imposed by substituting single valve for double valve disease in the Ross procedure is substantial, the advancement of percutaneous reinterventions on the RVOT presents a promising solution for delaying surgical reinterventions in selected patients.
Thromboembolism, Bleeding, and Endocarditis
One of the most important advantages of the Ross procedure is its low thrombogenicity and avoidance of anticoagulation therapy. This is reflected by our results of exceedingly low rates of thromboembolism and bleeding, comparable to the age-and sex-matched general population. 30 Endocarditis rates are also low, approximately half the endocarditis rates previously reported for mechanical AVR in patient populations with comparable proportions of preoperative endocarditis.
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Valve Selection and Implications for Practice
In prosthetic valve selection, the risk of valve deterioration and subsequent reintervention associated with biological valve substitutes, such as the Ross procedure, is generally weighed against mechanical valve-associated thromboembolism and bleeding risk. In growing children, the Ross procedure is often considered the preferred surgical option as it is the only living valve substitute and shows diameter increase along with somatic growth. 31 However, in older adolescents and nonelderly adults, a mechanical valve is often recommended because of its superior durability, despite the relatively high risk of thromboembolic and bleeding events, inferior hemodynamics, substantial excess mortality, and subsequent implications for pregnancy and lifestyle. 13 The 2017 US guidelines for the management of adult valvular heart disease propose the Ross procedure to be reserved for patients in whom anticoagulation is contraindicated, and the 2017 European guidelines do not even mention the Ross procedure at all. 32, 33 However, our results suggest that the Ross procedure may be beneficial to a larger group of selected patients when performed in centers of expertise. Owing to its excellent hemodynamics and long-term survival, low risks of thromboembolism, bleeding and endocarditis, absence of valve sounds, avoidance of the inconvenience and risks of anticoagulation therapy, and continuous improvements in the safety and outcome of reinterventions, the Ross procedure provides an outcome profile in stark contrast to that of mechanical AVR. This provides a unique opportunity for patients whose pref-erences, lifestyles, and life planning do not align with the outcome profile of mechanical AVR. In this light, conveyance of patient-tailored evidence-based risks and benefits of all treatment options in a shared decision-making process is of great importance. 32, 33 Innovative solutions such as patient information portals and decision aids may prove useful in this setting. 34, 35 Also, although the risk of reintervention after mechanical AVR is low, it is certainly not absent and should also be taken into consideration in the process of prosthetic valve selection. This also applies to the risk of thromboembolism and bleeding after AVR with biological alternatives.
Continuous advances in the design of bioprostheses are hypothesized to improve the durability of modern bioprostheses. This has led to an increase in their use in younger patients. Further development and studies on their long-term performance in young adult patients are required to shed light on their potential as a valve substitute in young adults.
Lastly, continuous improvements in aortic valve repair techniques may increasingly provide options for native valve preservation in young adult patients, avoiding or postponing the need for valve replacement. 36 Our outcomes provide a unique insight into what patients can be expected to face during the course of their lives after undergoing the Ross procedure, which represents valuable information to patients and clinicians in a meaningful format. This provides the opportunity to provide patients the essential information they need to support decision-making and improve treatment adherence, follow-up compliance, health behaviors, and quality of life. 34 Our methodology also provides the basis for patient-tailored decision-making by allowing for the possibility to generate patient-tailored outcome estimates. Although we were currently only able to tailor our outcome estimates to age, further studies on the relationship between other patient-related factors and outcomes will make it possible to further tailor outcome estimates, taking other factors into account such as underlying cause of disease, hemodynamics, symptoms, medical history, and concomitant diseases. This may aid clinicians and patients in more accurately selecting the optimal treatment for each individual patient. This methodology may also provide similar opportunities in other areas of cardiovascular medicine in which long-term outcome modeling and subsequent evidence-based decision-making remain a challenge.
Furthermore, because of continuous improvements in long-term survival, quality of life (as opposed to length of life) is increasingly coming into focus. Our outcomes show that, while life expectancy after the Ross procedure approaches the life expectancy of the general population, patients may face numerous valve-related events during their lives. How these valve-related events impact quality of life in these patients remains to be elucidated, although the Ross procedure has been previously shown to be associated with superior quality of life compared with mechanical AVR and comparable to aortic valve repair. 37 The lifetime event occurrence estimates provided by our methodology may provide the basis for estimating long-term quality of life in these patients and may inform efforts aimed at improving this.
Strengths and Limitations
To our knowledge, this is the first and only systematic review on this subject to use our advanced methods of meta-analysis of time-to-event data and microsimulation. These methods in conjunction with the large sample size allow us to provide robust long-term outcome estimates and age-specific estimates of life expectancy and lifetime event risk, allowing for a much better insight into long-term outcome in these patients and providing information that is crucial in decision-making and patient information.
This study has several limitations. It is a systematic review and meta-analysis of observational studies, many of which are retrospective in design. As such, the inherent limitations of meta-analyses and pooling data from retrospective observational studies should be taken into consideration. 38 Selection bias may have affected the observed outcomes, as unpublished data, abstracts, and presentations were not included. Funnel plots could not be used to investigate publication bias, as funnel plots do not allow for meaningful interpretation in case of absolute risk outcomes (as are all of our outcomes) because of substantial methodological limitations which may in itself give rise to funnel plot asymmetry. 39 Direct comparisons with alternative valve prostheses are hampered by the lack of published comparative data. Finally, there are limitations to the microsimulation model that should be taken into account. The relationship between the occurrence rates of valverelated events after the Ross procedure and age and history of previous valve-related events remains poorly defined and could, thus, not be incorporated into our microsimulation model. The model requires assumptions to be made about the evolution of event occurrence rates beyond the observed follow-up period, which may have introduced uncertainty, although this uncertainty is incorporated in the 95% credible intervals of our outcome estimates.
Conclusions
Outcome after the Ross procedure is characterized by excellent survival and low postoperative rates of thromboembolism, bleeding, and endocarditis. Lifetime risk of reintervention is high, mainly because of age-dependent structural valve deterioration of both the autograft and allograft. The Ross procedure provides a unique opportunity for patients whose preferences, lifestyles, and life planning do not align with the outcome provided by mechanical valve replacement and for growing children who also benefit from autograft diameter increase along with somatic growth. Thus, patients who are facing AVR are entitled to conveyance of evidencebased estimates of the risks and benefits of all treatment options in a shared decision-making process. Our results warrant reintroduction of the Ross procedure as a valuable option on the surgical menu for selected patients.
